[In symptomatic, nonhospitalized unvaccinated adults with mild to moderate COVID-19 at risk for progression to severe disease, does nirmatrelvir/ritonavir decrease the risk of COVID-19-related hospitalization or all-cause mortality while being safe?]
Revue de Medecine Interne
; 28:28, 2022.
Article
in French
| MEDLINE | ID: covidwho-1740153
Full text:
Available
Collection:
Databases of international organizations
Database:
MEDLINE
Type of study:
Prognostic study
Language:
French
Journal:
Revue de Medecine Interne
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS